Claims for Patent: 10,799,473

Summary for Patent: 10,799,473

Title:	Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
Abstract:	Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade. Also provided is a composition for use in reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation, the composition comprising a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.
Inventor(s):	Day; Regina M (Rockville, MD), Panganiban; Ronald-Allan M (Bethesda, MD)
Assignee:	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Bethesda, MD)
Application Number:	14/771,171
Patent Claims:	1. A method of reducing cellular senescence in non-cancerous keratinocytes that have been exposed to ionizing radiation, the method comprising administering to a subject before, after, or concurrently with exposure to ionizing radiation a compound that inhibits activation of an insulin-like growth factor-1 receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade, wherein the compound is administered in an amount effective to reduce cellular senescence in non-cancerous keratinocytes in the subject, wherein the subject has skin cancer, and wherein the subject does not have prostate cancer. 2. The method of claim 1, wherein the compound that inhibits activation of the IGF-1R is an IGF-1R inhibitor. 3. The method of claim 1, wherein the compound that inhibits activation of the IGF-1R is an insulin growth factor-1 (IGF-1) inhibitor or an insulin growth factor-2 (IGF-2) inhibitor. 4. The method of claim 1, wherein the compound is an antibody. 5. The method of claim 4, wherein the antibody binds to IGF-1R. 6. The method of claim 2, wherein the IGF-1R inhibitor is BMS 754807; OSI-906; figitumumab (CP-751871); NT52; INSM-18; NVP-AEW541; NVP-ADW742; aIR3; IGF1R scFv-Fc; 486/STOP; 950/STOP; N-(2-methoxy-5-chlorophenyl)-N'-(2-methylquinolin-4-yl)- urea; BMS-754807; IGF-IRi; AG1024; R1507; AXL-1717; picropodophyllotoxin; PQ401; dalotuzumab; A-928605; KW-2450; BMS-536924; IMC-Al2; CP-751871; n-(5-chloro-2-methoxyphenyl)-N'-(2-methoxyquinolin-4-yl)-urea; TAE226; BMS-554417; MK-0646; BMS-536924; MAE87; XL 228; AGL 2263; I-OMe-AG538; AG538; OSI-868; BMS-754807; ADW742; NVP-ADW642; R1507; MK-0646; A928605; MAB391; BMS-536942; IMC-Al2; rhIGFBP3, ANT-429, ATL-1101, BVP-51004, JV-1-38, pegvisomant, A-928605, or PPP (CAS 477-47-4). 7. The method of claim 6, wherein the IGF-1R inhibitor is AG1024. 8. The method of claim 3, wherein the IGF-1 inhibitor is PPP (CAS 477-47-4). 9. The method of claim 1, wherein the compound that inhibits a protein involved in an IGF-1R induced signaling cascade is a PI3K inhibitor or an IRS-1 inhibitor. 10. The method of claim 9, wherein the PI3K inhibitor is Ly294002, Wortmannin, BEZ235 (NVP-BEZ235), GDC-0941, PI-103, BKM120 (NVP-BKM120), CAL-101 (GS-1101), IC-87114, GSK2636771, TG 100713, BYL719, PI3K/HDAC inhibitor 1, 3-Methyladenine, YM201636, NVP-BGT226, BAY80-6946, PF-04691502, PKI-402, CH5132799, GDC-0980 (RG7422), NU 7026, NU 7441 (KU-57788), AS-252424, AS-604850, AS-041164, CAY10505, GSK2126458, A66, PF-05212384 (PKI-587), PIK-294, PIK-293, XL765, PIK-93, AZD6482, AS-605240, GSK1059615, TG100-115, PIK-75, PIK-90, TGX-115, TGX-221, XL147, ZSTK474, quercetin, tetrodotoxin citrate, thioperamide maleate, PI103, (-)-deguelin, OSU03012, tandutinib, GSK690693, KU-55933, MK-2206, perifosine, triciribine, PI828, WHI-P 154, compound 15e,17-P-hydroxywortmannin, Pp 121, PX-478, PX-866, PX-867, WAY-266176, WAY-266175 SF1126, 07-112, IC-486068, or LME00084. 11. The method of claim 10, wherein the PI3K inhibitor is LY-294002. 12. The method of claim 1, wherein IGF-1R or the compound that inhibits a protein involved in an IGF-1R induced signaling cascade is administered before, after, or concurrently with exposure to ionizing radiation to protect non-cancerous keratinocytes in the subject from radiation-induced cellular senescence. 13. The method of claim 1, where the compound that inhibits a protein involved in an IGF-1R induced signaling cascade is administered no more than 14, 7, 6, 5, 4, 3, 2, or 1 days before or after the subject is exposed to ionizing radiation. 14. The method of claim 12, wherein the compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or the compound that inhibits a protein involved in an IGF-1R induced signaling cascade is administered concurrently with exposure to ionizing radiation. 15. The method of claim 1, wherein the subject is a mammal. 16. The method of claim 1, wherein the subject is a human. 17. A method of reducing cellular senescence in non-cancerous cells that have been exposed to ionizing radiation, the method comprising administering to a subject before, after, or concurrently with exposure to ionizing radiation a compound that inhibits activation of an insulin-like growth factor-1 receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade, wherein the compound is administered in an amount effective to reduce cellular senescence in non-cancerous cells in the subject, wherein the subject has been accidently exposed to ionizing radiation.

Details for Patent 10,799,473

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	March 25, 2003	10,799,473	2034-03-03
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	July 31, 2014	10,799,473	2034-03-03